Kaoru Kubota

32.4k total citations · 1 hit paper
269 papers, 7.1k citations indexed

About

Kaoru Kubota is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kaoru Kubota has authored 269 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Oncology, 171 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Kaoru Kubota's work include Lung Cancer Treatments and Mutations (131 papers), Lung Cancer Research Studies (96 papers) and Lung Cancer Diagnosis and Treatment (60 papers). Kaoru Kubota is often cited by papers focused on Lung Cancer Treatments and Mutations (131 papers), Lung Cancer Research Studies (96 papers) and Lung Cancer Diagnosis and Treatment (60 papers). Kaoru Kubota collaborates with scholars based in Japan, United States and South Korea. Kaoru Kubota's co-authors include Yutaka Nishiwaki, Nagahiro Saijo, Tomohide Tamura, Hironobu Ohmatsu, Kōichi Goto, Akihiko Gemma, Yuichiro Ohe, Ikuo Sekine, Seiji Niho and Kiyoyuki Furuse and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Kaoru Kubota

255 papers receiving 7.0k citations

Hit Papers

Randomized phase III study of cisplatin plus irinotecan v... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    2006 515 citations Yuichiro Ohe, Kaoru Kubota et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaoru Kubota Japan 44 4.4k 3.7k 1.5k 803 767 269 7.1k
Philip Bonomi United States 42 4.9k 1.1× 4.4k 1.2× 2.1k 1.4× 648 0.8× 652 0.9× 241 8.0k
Antônio Rossi Italy 45 3.9k 0.9× 3.8k 1.0× 2.3k 1.5× 1.1k 1.3× 944 1.2× 365 8.3k
Jeffrey Crawford United States 48 6.8k 1.6× 2.8k 0.8× 1.4k 0.9× 686 0.9× 834 1.1× 206 10.2k
Ikuo Sekine Japan 38 3.3k 0.8× 3.0k 0.8× 1.3k 0.8× 894 1.1× 743 1.0× 228 5.8k
Olivier Mir France 43 2.9k 0.7× 2.8k 0.7× 1.2k 0.8× 760 0.9× 655 0.9× 287 6.4k
Rossana Berardi Italy 45 4.2k 1.0× 2.8k 0.8× 1.9k 1.2× 1.1k 1.4× 569 0.7× 344 7.4k
Emilio Bria Italy 46 4.0k 0.9× 2.8k 0.8× 1.8k 1.2× 953 1.2× 495 0.6× 392 7.1k
James L. Wade United States 45 4.3k 1.0× 2.0k 0.5× 1.3k 0.9× 796 1.0× 484 0.6× 153 7.6k
Martin J. Edelman United States 52 4.6k 1.0× 4.3k 1.2× 2.0k 1.3× 1.0k 1.3× 544 0.7× 302 8.7k
Massimo Di Maïo Italy 50 5.1k 1.2× 3.9k 1.0× 2.0k 1.3× 1.1k 1.3× 1.0k 1.4× 403 9.3k

Countries citing papers authored by Kaoru Kubota

Since Specialization
Citations

This map shows the geographic impact of Kaoru Kubota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaoru Kubota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaoru Kubota more than expected).

Fields of papers citing papers by Kaoru Kubota

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaoru Kubota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaoru Kubota. The network helps show where Kaoru Kubota may publish in the future.

Co-authorship network of co-authors of Kaoru Kubota

This figure shows the co-authorship network connecting the top 25 collaborators of Kaoru Kubota. A scholar is included among the top collaborators of Kaoru Kubota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaoru Kubota. Kaoru Kubota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakamichi, Shinji, Kaoru Kubota, Toshihiro Misumi, et al.. (2024). Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study). Clinical Cancer Research. 30(6). 1104–1110. 8 indexed citations
2.
Nakamichi, Shinji, Takehiro Tozuka, Rintaro Noro, et al.. (2023). Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma. Internal Medicine. 62(18). 2731–2735. 4 indexed citations
3.
Shimokawa, Tsuneo, Hiroaki Okamoto, Ryunosuke Machida, et al.. (2023). Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer. 181. 107195–107195. 4 indexed citations
4.
Inui, Naoki, Yukihiro Toi, Yasuto Yoneshima, et al.. (2023). Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase. Advances in Therapy. 40(11). 4928–4944. 5 indexed citations
5.
Kondo, Tetsuro, Kaoru Kubota, Shinji Nakamichi, et al.. (2023). 1294P A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study). Annals of Oncology. 34. S746–S747. 1 indexed citations
6.
Miyanaga, Akihiko, Takehiro Tozuka, Yozo Sato, et al.. (2023). Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and Therapy. Volume 16. 465–470. 2 indexed citations
7.
Matsuda, Ayako, Kazue Yamaoka, Hideo Kunitoh, et al.. (2023). Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. Quality of Life Research. 32(9). 2629–2637. 2 indexed citations
8.
Nakamichi, Shinji, Kaoru Kubota, Masaru Matsumoto, et al.. (2023). Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study. International Journal of Clinical Oncology. 28(7). 872–879.
9.
Vollmann, Manja, Ayako Matsuda, Judith R. Kroep, et al.. (2020). <p>Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study</p>. Patient Related Outcome Measures. Volume 11. 67–71. 8 indexed citations
10.
Horinouchi, Hidehito, Kaoru Kubota, Akihiko Miyanaga, et al.. (2018). Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. ESMO Open. 3(1). e000288–e000288. 11 indexed citations
11.
Kogure, Yoshihito, Hideo Saka, Yuichi Takiguchi, et al.. (2018). A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer. 19(5). e711–e715. 8 indexed citations
12.
Sugano, Teppei, Masahiro Seike, Rintaro Noro, et al.. (2015). Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 14(11). 2433–2440. 57 indexed citations
13.
Kanda, Shintaro, Hidehito Horinouchi, Yutaka Fujiwara, et al.. (2015). Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89(3). 287–293. 27 indexed citations
14.
Kitamura, Kazuhiro, Masahiro Seike, Tetsuya Okano, et al.. (2013). MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells. Molecular Cancer Therapeutics. 13(2). 444–453. 161 indexed citations
15.
Kawahara, Masaaki, Shinji Atagi, Kiyoshi Komuta, et al.. (2013). Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.. PubMed. 33(10). 4631–7. 6 indexed citations
16.
Kubota, Kaoru, Seiji Niho, Sotaro Enatsu, et al.. (2009). Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study. Journal of Thoracic Oncology. 4(12). 1530–1536. 23 indexed citations
17.
Ishii, Genichiro, Atsushi Ochiai, Kiyotaka Yoh, et al.. (2006). Eg5 expression is closely correlated with response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Cancer Research. 66. 1065–1065. 1 indexed citations
18.
Kubota, Kaoru, et al.. (1997). [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].. PubMed. 34(5). 329–36. 5 indexed citations
19.
Sakatani, Mitsunori, et al.. (1995). [Primary pulmonary cryptococcosis with pleural effusion, and clinical studies of five cases].. PubMed. 33(12). 1430–5. 2 indexed citations
20.
Mizoguchi, H & Kaoru Kubota. (1978). An improved plasma culture system for the production of megakaryocyte colonies in vitro.. PubMed. 41(6). 1352–8. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Antônio Rossi Breakdown of academic impact, for papers by Jeffrey Crawford Breakdown of academic impact, for papers by Ikuo Sekine Breakdown of academic impact, for papers by Olivier Mir Breakdown of academic impact, for papers by Rossana Berardi Breakdown of academic impact, for papers by Emilio Bria Breakdown of academic impact, for papers by James L. Wade Breakdown of academic impact, for papers by Martin J. Edelman Breakdown of academic impact, for papers by Massimo Di Maïo
Rankless by CCL
2026